Beam Therapeutics (BEAM) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.28

Estimate

-$1.17

Surprise

-9.4%

Revenue (period 2026-09-30)

$307,000

Score today

4.5/10

Revenue source: xbrl.

Beam Therapeutics (BEAM) reported a wider loss than forecast — adjusted EPS of -$1.28 against the -$1.17 estimate (a 9.4% shortfall).

• Wedbush Adjusts Price Target on Beam Therapeutics — fiscal.ai, 2026-11-03
• Beam Therapeutics Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-03
• Beam Therapeutics Q3 EPS $(1.28) Misses $(1.15) Estimate, Sales $307.000K Miss $8.752M Estimate — benzinga, 2026-11-03

TrendMatrix currently rates BEAM Sell at 4.5/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -9.4% surprise compares with a +76.2% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$26.33

Price target

$42.96

Stop

$24.49

Upside to target

+63.2%

Reward-to-risk

5.2:1

Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.72B

P/E (fwd)

-5.3

52-week range

$20.23–$38.26

Off 52-week high

31.2%

RSI (14)

60

Volume vs avg

0.77×

Score today

4.5/10